JP2024535925A - 修飾されたインターロイキンｐ４０サブユニットタンパク質及びその使用方法 - Google Patents

修飾されたインターロイキンｐ４０サブユニットタンパク質及びその使用方法 Download PDF

Info

Publication number
JP2024535925A
JP2024535925A JP2024519345A JP2024519345A JP2024535925A JP 2024535925 A JP2024535925 A JP 2024535925A JP 2024519345 A JP2024519345 A JP 2024519345A JP 2024519345 A JP2024519345 A JP 2024519345A JP 2024535925 A JP2024535925 A JP 2024535925A
Authority
JP
Japan
Prior art keywords
domain
amino acid
modified
fusion protein
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535925A5 (https=
Inventor
ライアン ブラックラー
フォン クロイデンシュタイン トーマス シュプレター
Original Assignee
ザイムワークス ビーシー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザイムワークス ビーシー インコーポレイテッド filed Critical ザイムワークス ビーシー インコーポレイテッド
Publication of JP2024535925A publication Critical patent/JP2024535925A/ja
Publication of JP2024535925A5 publication Critical patent/JP2024535925A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024519345A 2021-09-29 2022-09-29 修飾されたインターロイキンｐ４０サブユニットタンパク質及びその使用方法 Pending JP2024535925A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163249685P 2021-09-29 2021-09-29
US63/249,685 2021-09-29
PCT/CA2022/051445 WO2023050006A1 (en) 2021-09-29 2022-09-29 Modified interleukin p40 subunit proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024535925A true JP2024535925A (ja) 2024-10-02
JP2024535925A5 JP2024535925A5 (https=) 2025-09-24

Family

ID=85780291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519345A Pending JP2024535925A (ja) 2021-09-29 2022-09-29 修飾されたインターロイキンｐ４０サブユニットタンパク質及びその使用方法

Country Status (9)

Country Link
US (1) US20240228567A1 (https=)
EP (1) EP4408870A4 (https=)
JP (1) JP2024535925A (https=)
KR (1) KR20240068070A (https=)
CN (1) CN118043343A (https=)
AU (1) AU2022355496A1 (https=)
CA (1) CA3232071A1 (https=)
MX (1) MX2024003940A (https=)
WO (1) WO2023050006A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI880235B (zh) 2017-11-28 2025-04-11 日商中外製藥股份有限公司 可調整配體結合活性的配體結合分子
WO2025136986A2 (en) 2023-12-18 2025-06-26 Genzyme Corporation Il-12 loss of potency muteins
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019355971B2 (en) * 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
JP7773991B2 (ja) * 2020-03-23 2025-11-20 ザイムワークス ビーシー インコーポレイテッド マスクされたｉｌ１２融合タンパク質及びその使用方法

Also Published As

Publication number Publication date
US20240228567A1 (en) 2024-07-11
EP4408870A4 (en) 2025-10-22
CA3232071A1 (en) 2023-04-06
AU2022355496A1 (en) 2024-05-02
WO2023050006A1 (en) 2023-04-06
CN118043343A (zh) 2024-05-14
MX2024003940A (es) 2024-04-22
EP4408870A1 (en) 2024-08-07
KR20240068070A (ko) 2024-05-17

Similar Documents

Publication Publication Date Title
JP7773991B2 (ja) マスクされたｉｌ１２融合タンパク質及びその使用方法
US20230227584A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
CN112424228B (zh) 新型双特异性激动性4-1bb抗原结合分子
US20240043535A1 (en) IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULES
JP7148539B2 (ja) 免疫抱合体
CN113677403B (zh) 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
JP7675083B2 (ja) 新規４－１ｂｂｌ三量体含有抗原結合分子
US20240228567A1 (en) Modified interleukin p40 subunit proteins and methods of use thereof
CN114127123A (zh) 结合cea的抗体与4-1bbl的融合
EP3703746A1 (en) Novel tnf family ligand trimer-containing antigen binding molecules
WO2024039973A2 (en) Masking polypeptide, activatable novel prodrugs and methods of use thereof
WO2025133042A2 (en) Activatable fusion proteins and methods of use
HK40110021A (zh) 经修饰的白细胞介素p40亚基蛋白质及其使用方法
HK40085919A (en) Masked il12 fusion proteins and methods of use thereof
US20250333542A1 (en) Interferon gamma variants and antigen binding molecules comprising these
HK40119034A (zh) 干扰素γ变体以及包含这些变体的抗原结合分子
KR20260030113A (ko) 항체 및 그의 용도
HK40091599A (zh) 免疫活化fc结构域结合分子
HK40075193A (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
CN116997362A (zh) 含调节免疫细胞功能的cd8抗原结合分子的融合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250912